Why does the coating matter for serrapeptase?

Serrapeptase is a proteolytic enzyme that denatures at the acidic pH of the stomach (approximately pH 1–2). An enteric coating — a polymer shell that resists gastric acid but dissolves in the higher-pH small intestine — protects the enzyme so it can be absorbed intact. The human randomized trials reporting statistically significant reductions in post-surgical swelling used enteric-coated oral formulations (PMID 33653320, a randomized trial in 133 adults; PMID 18272344, a crossover randomized trial in 24 adults).

What do SPU and SU units mean on a serrapeptase label?

SPU (Serratiopeptidase Units) and SU (Serrapeptase Units) are enzyme-activity measurements that reflect how much substrate the enzyme can break down under standardized conditions. Because enzyme activity per milligram varies across manufacturers and processing methods, activity units are a more meaningful quality indicator than milligrams alone. Human trials have used formulations roughly equivalent to 5–10 mg (approximately 10,000–20,000 SPU).

What does the research actually show about serrapeptase?

The best available evidence comes from small-to-moderate randomized trials in surgical contexts. A 2021 randomized trial in 133 adults found serratiopeptidase reduced trismus and facial swelling after impacted third-molar removal vs placebo (PMID 33653320). A 2008 crossover randomized trial in 24 adults reported reductions in cheek swelling and pain at 2–7 days post-operatively vs placebo (PMID 18272344). A 1989 randomized trial in 66 patients found ~50% reduction in ankle swelling by day 3 post-surgery vs controls (PMID 2647603). Evidence is mixed — one 2009 randomized trial in 150 patients found no significant anti-inflammatory advantage over placebo in a dental model (PMID 19168326). Effects outside surgical contexts are less well studied. Always consult a healthcare provider.

Is serrapeptase safe?

Short-term use at studied doses (5–10 mg enteric-coated) has been reported as generally well-tolerated in randomized trials. Serrapeptase has proteolytic activity and should be used cautiously by individuals on anticoagulant medications or with bleeding disorders. It is not a substitute for prescribed anti-inflammatory medications. Consult a healthcare provider before use, particularly if taking other medications.

Moderate Evidence

Best Form of Serrapeptase

Enteric-coated serrapeptase may preserve enzyme activity through the acidic stomach environment; the randomized trials reporting post-surgical swelling support used this formulation — though direct comparison data between coated and uncoated products in humans is currently limited.

Updated 2026 · Reviewed by Dr. Brennan Commerford, D.C.

All Forms Ranked by Evidence

—
Verification pending
Peptizyme SP
Form: Branded Enzyme
Evidence for this form is under review — no score is shown until it is verified.
—
Verification pendingFF Preferred
Serratiopeptidase (250,000 U/GM)
Form: 250,000 U/GM
Evidence for this form is under review — no score is shown until it is verified.
—
Verification pending
Serrepeptidase
Form: Generic
Evidence for this form is under review — no score is shown until it is verified.

Editorial note

Serrapeptase is a protease derived from Serratia marcescens that is rapidly inactivated at gastric pH; enteric coating is the accepted mechanism for protecting the enzyme through the stomach so it can be absorbed in the small intestine. Human randomized trials demonstrating anti-edema and anti-trismus effects used enteric-coated oral tablets (PMID 33653320, a randomized trial in 133 adults; PMID 18272344, a crossover randomized trial in 24 adults). Importantly, the human PK evidence base is limited: no head-to-head enteric-coated vs non-coated bioavailability trial was identified in PubMed, so the enteric-coating benefit rests on mechanistic enzyme-stability rationale and formulation convention rather than a dedicated absorption study.

All Forms Compared

Enteric-Coated, Activity-Standardized

Best For

General use whenever serrapeptase supplementation is intended

The positive human randomized trials (PMID 33653320, PMID 18272344) used enteric-coated formulations. Look for activity labeled in SPU or SU units (10,000–60,000 SPU is a common range); mg alone is insufficient because enzyme activity per mg can vary by manufacturer.

Delayed-Release / Enteric-Coated Capsule

Best For

Swallowing ease; same acid-protection rationale as enteric-coated tablet

Delayed-release capsule technology achieves the same acid-protection goal as a tablet enteric coat. Confirm the label specifies delayed-release or enteric and provides activity in SPU/SU rather than mg only.

Non-Enteric-Coated (Standard Capsule/Tablet)

Best For

Not recommended as primary form

Proteolytic enzymes including serrapeptase are structurally denatured at gastric pH. Without enteric protection, a significant fraction is expected to be inactivated before reaching the small intestine. No positive human efficacy data were identified for the non-enteric-coated form.

Liposomal Serrapeptase

Best For

Experimental; insufficient data to recommend over enteric-coated forms

Marketed as offering enhanced uptake, but no peer-reviewed human bioavailability or efficacy data for liposomal serrapeptase were identified in PubMed as of 2026. Insufficient evidence to prefer it over established enteric-coated forms.

Frequently Asked Questions

Why does the coating matter for serrapeptase?: Serrapeptase is a proteolytic enzyme that denatures at the acidic pH of the stomach (approximately pH 1–2). An enteric coating — a polymer shell that resists gastric acid but dissolves in the higher-pH small intestine — protects the enzyme so it can be absorbed intact. The human randomized trials reporting statistically significant reductions in post-surgical swelling used enteric-coated oral formulations (PMID 33653320, a randomized trial in 133 adults; PMID 18272344, a crossover randomized trial in 24 adults).
What do SPU and SU units mean on a serrapeptase label?: SPU (Serratiopeptidase Units) and SU (Serrapeptase Units) are enzyme-activity measurements that reflect how much substrate the enzyme can break down under standardized conditions. Because enzyme activity per milligram varies across manufacturers and processing methods, activity units are a more meaningful quality indicator than milligrams alone. Human trials have used formulations roughly equivalent to 5–10 mg (approximately 10,000–20,000 SPU).
What does the research actually show about serrapeptase?: The best available evidence comes from small-to-moderate randomized trials in surgical contexts. A 2021 randomized trial in 133 adults found serratiopeptidase reduced trismus and facial swelling after impacted third-molar removal vs placebo (PMID 33653320). A 2008 crossover randomized trial in 24 adults reported reductions in cheek swelling and pain at 2–7 days post-operatively vs placebo (PMID 18272344). A 1989 randomized trial in 66 patients found ~50% reduction in ankle swelling by day 3 post-surgery vs controls (PMID 2647603). Evidence is mixed — one 2009 randomized trial in 150 patients found no significant anti-inflammatory advantage over placebo in a dental model (PMID 19168326). Effects outside surgical contexts are less well studied. Always consult a healthcare provider.
Is serrapeptase safe?: Short-term use at studied doses (5–10 mg enteric-coated) has been reported as generally well-tolerated in randomized trials. Serrapeptase has proteolytic activity and should be used cautiously by individuals on anticoagulant medications or with bleeding disorders. It is not a substitute for prescribed anti-inflammatory medications. Consult a healthcare provider before use, particularly if taking other medications.

See how Enteric-Coated, Activity-Standardized fits your formula

Preview a personalized formula using research-backed dosing.

Preview your formula →

Deep dive: Enteric-Coated, Activity-Standardized (in SPU/SU units) research

Full ingredient spotlight with citations

View spotlight

FormulaForge formulates and sells supplements containing the ingredients discussed on this page. Our formulary recommendations are based on peer-reviewed bioavailability research. All cited studies are independently verifiable.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.